Nektar Therapeutics (LTS:0UNL)
$ 1.0304 -0.0065 (-0.63%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.86 GF Score: 53/100

Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Transcript

Apr 25, 2022 / 09:00PM GMT
Release Date Price: $4.71 (+4.43%)
Operator

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Analyst and Investor Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Please go ahead.

Jennifer Ruddock
Nektar Therapeutics - SVP of Strategy & Corporate Affairs

Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. With us on the call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; and Dr. Jonathan Zalevsky, our Chief of Research and Development; and our newly appointed Chief Medical Officer, Dr. Brian Kotzin.

On today's call, we expect to make forward-looking statements regarding our business, including clinical trials, enrollment and clinical trials results, timing and plans for future clinical trials, timing and plans for future clinical data presentations, the therapeutic potential of our drug candidates, outcomes and plans

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot